Related references
Note: Only part of the references are listed.Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction Results of DAPA-HF
Pardeep S. Jhund et al.
CIRCULATION (2021)
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction The EMPEROR-Reduced Trial
Milton Packer et al.
CIRCULATION (2021)
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT
Prakriti Gaba et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction
M. A. ap Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Stefan D. Anker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis
Rhanderson Cardoso et al.
ECLINICALMEDICINE (2021)
Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association
Salim S. Virani et al.
CIRCULATION (2020)
Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)
Kevin Damman et al.
EUROPEAN JOURNAL OF HEART FAILURE (2020)
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
Mark C. Petrie et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease Results of the VERTIS CV Trial
Francesco Cosentino et al.
CIRCULATION (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
Eri T. Kato et al.
CIRCULATION (2019)
Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial
Stefan D. Anker et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
S. D. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure
Eric J. Velazquez et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Prescriber Patterns of SGLT2i After Expansions of US Food and Drug Administration Labeling
Muthiah Vaduganathan et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Risk and predictors of readmission for heart failure following a myocardial infarction between 2004 and 2013: A Swedish nationwide observational study
Liyew Desta et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project
Suzanne V. Arnold et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2017)
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials
Sven Kohler et al.
ADVANCES IN THERAPY (2017)
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
David Fitchett et al.
EUROPEAN HEART JOURNAL (2016)
The real-world evidence of heart failure: findings from 41 413 patients of the ARNO database
Aldo P. Maggioni et al.
EUROPEAN JOURNAL OF HEART FAILURE (2016)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Clinical Trial Participation After Myocardial Infarction in a National Cardiovascular Data Registry
Jacob A. Udell et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure
John J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Key multiplicity issues in clinical drug development
Alex Dmitrienko et al.
STATISTICS IN MEDICINE (2013)
The answer is 17 years, what is the question: understanding time lags in translational research
Zoe Slote Morris et al.
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE (2011)
Do we need to adjudicate major clinical events?
Christopher B. Granger et al.
CLINICAL TRIALS (2008)
External validity of clinical trials in acute myocardial infarction
Philippe Gabriel Steg et al.
ARCHIVES OF INTERNAL MEDICINE (2007)
Share Paper
